[US-헬스케어] 08/06 Wall St. Recap
LLYBULL As a senior equity analyst, I evaluate Eli Lilly and Co. (LLY) with an optimistic outlook despite recent short-term market volatility. The primary catalyst supporting this view is the successful Phase 3 clinical trial of its next-generation obesity treatment,…